ReviewWorld journal of urology2005
Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?
Review in World journal of urology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of the efficacy of sexual intercourse for distal ureteric stones.The Journal of international medical research · 2019Pooled it
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Sexual intercourse as a new option in the medical expulsive therapy of distal ureteral stones in males: a prospective, randomized, controlled study.International urology and nephrology · 2017Trial
- The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Efficacy of sexual stimulation in the treatment of distal ureteral stones: A meta-analysis.Heliyon · 2024Article
- Frequency-dependent characteristics of nerve-mediated ATP and acetylcholine release from detrusor smooth muscle.Experimental physiology · 2022Article
- Review
- Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra.Research and reports in urology · 2021Article
- Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.World journal of urology · 2020Review
- Review
- Urothelium muscarinic activation phosphorylates CBS(Ser227) via cGMP/PKG pathway causing human bladder relaxation through H2S production.Scientific reports · 2016Article
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms.Translational andrology and urology · 2016Review
- Control of urinary drainage and voiding.Clinical journal of the American Society of Nephrology : CJASN · 2015Review
- Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia.The Prostate · 2015Article
- Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?World journal of nephrology · 2015Article
- Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.Nature reviews. Urology · 2014Review
- PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.Current bladder dysfunction reports · 2013Article
- Mechanisms involved in the nitric oxide-induced vasorelaxation in porcine prostatic small arteries.Naunyn-Schmiedeberg's archives of pharmacology · 2011Article
- Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.Journal of endocrinological investigation · 2010Article
- Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.British journal of pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with alpha-adrenoceptor antagonists that reduce the tone of prostatic stromal and urethral smooth muscle has beneficial effects in patients with benign prostatic hyperplasia (BPH) and lower urinary tracts symptoms (LUTS) and has brought attention to regulatory mechanisms of smooth muscle contractility of the outflow region. The prostate, urethra and bladder neck are densely supplied by nitric oxide (NO)-synthase-containing nerves that cause relaxation upon activation. In various experimental models, altered function or activity of the NO/cGMP pathway of the bladder neck and urethra may be related to inappropriate or un-coordinated functions of the bladder outlet and detrusor, but causal connections between alterations in this signaling system, a dysfunctional bladder outlet, and the development of LUTS are not established for humans. The present review focuses on regulatory functions of smooth muscle contractility by the NO/cGMP-pathway in the bladder neck, urethra, and prostate. Disease-related alterations in the NO/cGMP-pathway, and putative options for pharmacological modification of this signaling pathway in the out-flow region are briefly discussed.
Indexed as
Identifiers
16283327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.